Hemodynamic analysis based on computational fluid dynamics (CFD) modelling is expected to improve risk stratification for patients with aortic aneurysms and dissections. However, the parameter settings in CFD simulations involve considerable variability and uncertainty. Additionally, the exact relationship between hemodynamic features and disease progression remains unclear. These challenges limit the clinical application of aortic hemodynamic models. This review presents a detailed overview of the workflow for CFD-based aortic hemodynamic analysis, with a focus on recent advancements in the field. We also conducted a systematic review of 27 studies with large sample sizes (n > 5) that examine the hemodynamic characteristics of aortic aneurysms and dissections. Some studies identified consistent relationships between hemodynamic features and disease progression, reinforcing the potential for clinical application of aortic hemodynamic models. However, limitations such as small sample sizes and oversimplified patient-specific models remain. These findings emphasize the need for larger, more detailed studies to refine CFD modelling strategies, strengthen the connection between hemodynamics and diseases, and ultimately facilitate the clinical use of aortic hemodynamic models in disease management.
Background: Total percutaneous closure for the site of femoral arterial puncture using Perclose ProGlide (PP) has become prevalent post-percutaneous endovascular aortic repair (EVAR) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO).Objective: To evaluate the safety and efficacy of total percutaneous closure of the femoral artery access site post-EVAR compared with VA-ECMO.Methods: This was a retrospective observational study conducted over 4 years, including 88 patients who underwent EVAR (64 patients) and VA-ECMO (24 patients). Perclose ProGlide devices were used in the femoral artery puncture sites closed percutaneously. In this study, technical success was defined as successful arterial closure of the common femoral artery (CFA) without additional surgical or endovascular procedures to prevent vessel leaking. Access site complications, including overt bleeding requiring transfusion or surgical intervention, minor bleeding, tinea cruris, pseudoaneurysm, and lymphocele, were recorded 24 h and 30 days after arterial closure.Results: Each group's technical success rates were 95.8% (VA-ECMO) and 92.2% EVAR, respectively. There were no differences in the periprocedural complications of major bleeding, pseudoaneurysm, minor bleeding, acute limb ischemia, and groin infection. Furthermore, we did not observe any complications such as arterial thrombosis, dissection, stenosis, arteriovenous fistula, hematoma, groin infection, or lymphocele at the access site by following-up an ultrasound examination. There was no significant difference in the technical success rate of percutaneous closure by the PP device in the EVAR and VA-ECMO oxygenation groups. Also, no periprocedural or 30-day complications were observed at the access site of the EVAR and VA-ECMO patients.
8 June 2022 in Computer Methods and Programs in Biomedicine
Ferroptosis, an iron-dependent form of regulated cell death, represents an emerging therapeutic vulnerability in colorectal cancer (CRC). However, the epigenetic mechanisms controlling ferroptosis sensitivity in CRC remain poorly understood. Here, we identify histone deacetylase 3 (HDAC3) as a pivotal epigenetic suppressor of ferroptosis. Both pharmacological inhibition and genetic knockdown of HDAC3 significantly enhanced ferroptosis sensitivity, as evidenced by elevated intracellular ferrous iron (Fe 2+ ) and lipid peroxidation. Mechanistically, inhibition of HDAC3 reduced the expression of nuclear factor erythroid 2–related factor 2 (NRF2), a master antioxidant transcription factor, thereby leading to downregulation of glutathione peroxidase 4 (GPX4), a central ferroptosis defense gene. Notably, NRF2 knockdown abolished GPX4 downregulation by HDAC3 inhibition, whereas GPX4 overexpression rescued the ferroptotic phenotype caused by HDAC3 depletion. Collectively, these findings define an HDAC3–NRF2–GPX4 axis that suppresses ferroptosis in CRC, and highlight HDAC3 as a potential therapeutic target for ferroptosis-based cancer treatment.